Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Hereditary Angioedema (Mar 2018)

Posted by Matt Breese on Mar 1, 2019

Find me on:

According to our recent payer coverage analysis for Hereditary Angioedema (HAE) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: Under the pharmacy benefit, more than 63% of the covered lives under commercial formularies have utilization management restrictions.

MMIT-Reality Check-HAE_1Q2019Data snapshot as of Q1 2019

Trends: Management of HAE cannot simply be a one-size-fits-all approach, as the condition is variable and patient specific. Via AIS Health. 

To read the full Reality Check on Hereditary Angioedema treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing